Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally.

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after stopping their prescription, ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

GLP-1 drugs like Ozempic and Mounjaro helped men with low testosterone raise their levels without hormone replacement in a ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

Weight-loss injections using GLP-1 receptor agonists mimic a natural hormone in the body that suppresses appetite, slows digestion, and promotes a lasting feeling of fullness.

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...

With increasing global demand for advanced weight loss solutions, Canadian consumers now have a new way to access the recently approved obesity treatment Zepbound. Online pharmacy DutyFreeMeds.com is ...

Morgan Stanley identifies 15 stocks with potential near-term catalysts for growth, offering insights on upcoming earnings and ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Stellantis reports a preliminary net loss of 2.3 billion euros ($2.68 billion) in the first half of the year. The automaker ...